Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (Aug 6, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 6, 2024
Period End
August 6, 2024
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. furnished a press release (Exhibit 99.1) reporting second-quarter 2024 results for the period ended June 30, 2024.

Total revenue was $231.4 milliona, up 5% from $221.0 million a year earlier. Royalty revenue rose 12% to $124.9 million, driven by Phesgo, the launch of VYVGART Hytrulo and the U.S. launch of Teriparatide. Net income was $93.2 million, compared with $74.8 million, and GAAP diluted EPS was $0.72 versus $0.56.

Adjusted EBITDA was $137.0 millionb, compared with $115.1 million, and non-GAAP diluted EPS was $0.91 versus $0.74. Cash, cash equivalents and marketable securities totaled $529.0 million at June 30, 2024, up from $336.0 million at December 31, 2023. The company reiterated its 2024 guidance, which was raised on June 6, 2024 following a new European patent covering the ENHANZE rHuPH20 product.

Guidance calls for total revenue of $935 million to $1,015 millionc (13% to 22% growth), royalty revenue of $520 million to $555 million (16% to 24% growth), adjusted EBITDA of $555 million to $615 million (30% to 44% growth) and non-GAAP diluted EPS of $3.65 to $4.05 (32% to 46% growth). The new European patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until March 2029. Royalties on DARZALEX SC were temporarily lowered in Europe between March and June 2024 before the patent was issued.

The company also completed a $250 milliond accelerated share repurchase in June 2024, retiring 6.5 million shares at $38.35 per share, which concluded a December 2021 program totaling 19.1 million shares repurchased at an average of $39.31 per share. Management pointed to upcoming partner regulatory events, including a PDUFA goal date of September 13, 2024 for Roche's ocrelizumab SC and a PDUFA goal date of December 29, 2024 for BMS's nivolumab SC.

Key Highlights

  1. Q2 2024 total revenue of $231.4 million, up from $221.0 million in Q2 2023 (5% increase), with royalty revenue up 12% to $124.9 million.
  2. Net income of $93.2 million versus $74.8 million; GAAP diluted EPS of $0.72 versus $0.56, and non-GAAP diluted EPS of $0.91 versus $0.74.
  3. Adjusted EBITDA of $137.0 million, compared with $115.1 million in the prior-year quarter; operating income was $117.2 million versus $94.5 million.
  4. 2024 guidance reiterated: total revenue of $935-$1,015 million, adjusted EBITDA of $555-$615 million, and non-GAAP diluted EPS of $3.65-$4.05, following a June 6, 2024 increase tied to a new European patent.
  5. Cash, cash equivalents and marketable securities of $529.0 million at June 30, 2024, up from $336.0 million at December 31, 2023.
  6. Completed a $250 million accelerated share repurchase in June 2024 (6.5 million shares at $38.35), concluding a December 2021 program with 19.1 million shares repurchased in total.
  7. Partner milestones included $15.0 million from BMS (FDA BLA acceptance), $7.0 million from BMS (EMA validation) and $3.0 million from Acumen, plus approvals of Ocrevus SC in the EU and UK and VYVGART Hytrulo for CIDP in the U.S.

Frequently Asked Questions

  1. How did Halozyme perform in the second quarter of 2024?

    Total revenue was $231.4 million, up from $221.0 million, with royalty revenue up 12% to $124.9 million. Net income was $93.2 million, GAAP diluted EPS was $0.72, and adjusted EBITDA was $137.0 million.

  2. Did Halozyme change its 2024 financial guidance?

    The company reiterated its 2024 guidance, which had been increased on June 6, 2024 because of a new European patent covering the ENHANZE rHuPH20 product. Guidance is total revenue of $935-$1,015 million, royalty revenue of $520-$555 million, adjusted EBITDA of $555-$615 million, and non-GAAP diluted EPS of $3.65-$4.05. The EPS guidance does not consider potential future share repurchases.

  3. What was the effect of the new European patent on DARZALEX SC royalties?

    The newly granted patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until the patent expires in March 2029. The filing notes that DARZALEX SC royalties were temporarily lowered in Europe between March and June 2024, before the patent was issued.

  4. What upcoming partner events does the company highlight?

    The company cites a PDUFA goal date of September 13, 2024 for Roche's ocrelizumab SC in the U.S. and a PDUFA goal date of December 29, 2024 for BMS's subcutaneous nivolumab. It also says Johnson & Johnson's amivantamab SC is on track for potential U.S. and EU launches in 2025.

  5. How much capital did Halozyme return to shareholders?

    The company completed a $250 million accelerated share repurchase in June 2024, repurchasing 6.5 million shares at $38.35 per share. This concluded a December 2021 program under which 19.1 million shares were repurchased over three years at an average of $39.31 per share.